Salagen Articles
Lannett's pilocarpine ANDA cleared by FDA
12 May 2009
Japan stock market week to May 28, 2007
4 June 2007
Actavis launches pilocarpine 7.5mg in USA
11 September 2006
FDA OKs IMPAX' generic Salagen
10 April 2006
Alpharma debuts authorized generic Salagen
28 February 2005
MGI's 3rd-qtr losses rocket on acquisitions
25 October 2004
MGI Pharma's 2nd-qtr sales rocket to $46.9M
26 July 2004
CIBA and MGI link up for Salagen in Europe
4 May 2000
Latest Wave Of US 1st Quarter Results
29 October 1998
MGI Pharma 2nd Qtr Approaching Breakeven
22 July 1998
US Quarterly Financial Results Round-Up
23 April 1998
MGI Pharma Promoting Salagen
8 April 1998
MGI's Salagen Approved For New Indication
26 February 1998
More US Year-End 1997 Corporate Results
24 February 1998
MGI Pharma On Verge Of Breaking Even
16 October 1997
MGI Pharma's Salagen Approved In Canada, New Indication
11 September 1997
Smaller US Firms' Losses Grow Due To R&D Costs
31 July 1997
Product Sales Up 40% At MGI Pharma
24 February 1997
MGI Pharma Submits sNDA For Salagen
17 February 1997
US Biopharma Cos Report 3rd-Qtr Financial Results
11 November 1996
MGI Pharma's Salagen For Sjogren's Syndrome
28 October 1996
MGI Pharma' Salagen Effective
1 July 1996
US Corporate Results Round-Up
26 February 1996
MGI Pharma's Salagen: new market approval
15 January 1996
Salagen goes to Taiwan
15 May 1995
Salagen Launch In UK
20 March 1995
MGI Licenses Salagen To Kissei In Japan
2 January 1995
MGI Deal With Upjohn
5 December 1994
Solid 3rd Qtr Growth For Large Pharma Cos
31 October 1994
MGI GRANTS SALAGEN RIGHTS TO KISSEI
27 June 1994
FIRST APPROVAL FOR MGI'S SALAGEN
28 March 1994
SMALL US DRUG COs POST QUARTERLY RESULTS
21 February 1994
MGI to TAKE '93 FOURTH QTR CHARGE
24 January 1994
SALAGEN APPROVABLE
10 January 1994
PILOCARPINE GIVES BENEFIT IN CANCER
23 August 1993
MGI PHARMA'S SALAGEN
6 April 1992
MGI PHARMA'S SALAGEN
6 April 1992
Showing 1-40 of 40 articles
- 1
- Is failure to adopt business process management putting the pharma industry at risk?
- New Zealand declines Alexion's funding application for Solaris
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
- Elan makes "transformational" acquisitions and a divestment
